TAIZHOU, China, Jan. 16, 2020 /PRNewswire/ --
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or
the "Company"), a specialty pharmaceutical company focusing on the
research, development, manufacturing, marketing, and sales of
Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced
TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs,
regular TCMPs, and TCM Homologous Supplements
("TCMHS") announced today that its DNA Exam Laboratory
completely built in October of 2019 recently has been approved by
Jiangsu province Drug
Administration (JSDA). The Laboratory has been granted to perform
research and development (R&D) and quality control of TCM raw
materials and TCMP products applying DNA testing technology.
The DNA testing technology can be extensively used for
developing new TCMP products, analyzing and examining in accordance
with highly specific standard of TCMP raw materials, and their
products, especially, the Advanced TCMPs. The new application of
the DNA testing technology would significantly enhance the
Company's R&D and the quality control capabilities, in
particular for the TCMP products which regulations require
achieving certain explicit standard.
Dr. Jingzhen Deng, Chief
Scientific Officer and Chief Operating Officer of China SXT,
commented, "The approval of our DNA Exam Laboratory is an
indication to our continuous effort in leading research and
development of TCMPs and our pursuit of the higher quality of our
products. We believe it is the first DNA Exam Laboratory set up by
TCMP pharmaceutical company and approved by the regulatory
administration. This will allows us to further strengthen our
R&D capabilities and advance our Advanced TCMPs in TCM
specialty pharmaceutical industry, which is expected to eventually
help expanding our market share in our TCMP products."
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu
Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Specifically, the Company's statements regarding the
closing of the proposed private placement are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; the growth of the pharmaceutical
market, particularly the Traditional Chinese Medicine Pieces
("TCMPs") market, in China; reputation and brand; the impact
of competition and pricing; government regulations; fluctuations in
general economic and business conditions in China and the
international markets the Company serves and assumptions underlying
or related to any of the foregoing and other risks contained in
reports filed by the Company with the Securities and Exchange
Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for review at www.sec.gov. The
Company undertakes no obligation to publicly revise these
forward - looking statements to reflect events or
circumstances that arise after the date hereof.
View original
content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announced-regulatory-approval-of-its-dna-exam-laboratory-300988031.html
SOURCE China SXT Pharmaceuticals, Inc.